Robert Andtbacka

Company: Seven and Eight Biopharmaceuticals

Job title: Chief Medical Officer

Seminars:

Considerations & Progress in Developing a Dual TLR Agonist 12:30 pm

Exploring the drug discovery process: target identification & validation, antitumor effect, pathway understanding, biomarkers Discussing potential indications? Latest data & future directionsRead more

day: Day One

Breakfast Panel Discussion: How Far Have We Come & Where Do We Want to Go? 9:30 am

Dissecting the recent advances in PRR-targeting drugs Sharing insights into the directions for more successful immune system manipulation Thoughts on modes of action being investigated, conclusions drawn from setbacks and ways to improve the clinical outcomes Pathway understanding, indications, toxicity outlooks, combinations, drug formats and delivery mechanisms Biological understanding update: pathway, biomarker and translational updates…Read more

day: Day One